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The propensity of various insulins and their analogs to oligomerize was investigated by mass
spectrometric methods including measurement of the relative abundances of oligomers in the
gas phase and the kinetics of H/D amide exchange. The kinetics of deuterium uptake show a
good fit when the exchanging amides are placed in three kinetic groups: fast, intermediate, and
slow. r-Human insulin, of the insulins investigated, has fewer amides that exchange at
intermediate rates and more that exchange at slow rates, in accord with its higher extent of
association in solution. We adapted PLIMSTEX (protein ligand interactions by mass spectrom-
etry, titration, and H/D exchange) to determine protein/ligand affinities in solution, to
determine self-association equilibrium constants for proteins, and to apply them to various
insulin analogs. We term this adaptation SIMSTEX (self-association interactions using mass
spectrometry, self-titration and H/D exchange); it gives affinity constants that compare well
with the literature results. The results from SIMSTEX show that some mutants (e.g., GlnB13)
have an increased tendency to self-associate, possibly slowing down their action in vivo. Other
mutants (e.g., lispro and AspB9) have lower propensities for self-association, thus providing
potentially faster-acting analogs for use in controlling diabetes. (J Am Soc Mass Spectrom
2006, 17, 1526–1534) © 2006 American Society for Mass SpectrometryInsulin, a protein with 51 amino acid residues in twochains, which are linked together by two disulfidebonds and is produced in the pancreas to regulate
blood glucose levels (Scheme 1), self-associates in solu-
tion [1, 2]. It is stored in the pancreas as a hexamer, but
the active form is a monomer [1, 2]. The hexamer must
dissociate into monomers for absorption into the blood
stream. An issue for r-human insulin and for any
analogs to be used in the treatment of diabetes is the
role of its structural form on the onset time and dura-
tion of action. One hypothesis is that the higher the
tendency of an insulin to self-associate, the longer it
takes to act [3].
In type 1 diabetes, insulin-producing cells are de-
stroyed, and blood glucose levels must be controlled by
injection of r-human insulin or its analogs. Strict control
of blood glucose levels is difficult because conventional
delivery methods do not mimic the quick physiological
release from the pancreas in response to the increased
glucose levels that follow a meal, for example [4].
r-Human insulin has an onset time of30 min, and 5 to
12 h of action [2, 4] and, therefore, one must administer
it 30 to 60 min before meals to achieve optimal control
of glucose levels [3, 5]. One reason for long onset for
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ciate to the monomeric form [2]; thus, insulin mutants
that readily dissociate into monomers should be faster-
acting [3, 5]. The effect of such mutations on oligomer-
ization also provides insight into intermolecular inter-
actions and points the way to the design of new insulin
analogs that are fast- or prolonged-acting [3, 6, 7]. Some
mutants, in fact, are reasonably well-understood and
are currently used in the treatment of diabetes [7, 8].
One FDA-approved analog of insulin is “lispro” [9],
a protein in which the amino acids in positions B28
(proline) and B29 (lysine) of the B-chain of human
insulin are exchanged. This simple switch causes a
decrease in the dimerization constant, leading to en-
hanced dissociation owing to the loss of key hydropho-
bic interactions in lispro compared with human insulin
[2, 9]. The orientation of Pro in the B-chain is towards
the dimer interface in human insulin (Scheme 2),
whereas it is facing away from the interface in lispro
(Scheme 3). The observation that most of the interac-
tions involved in dimerization occur in the C-terminal
region of the B-chain (except for AspA21) [10, 11] may
explain this significant effect on the oligomerization
tendency. The binding of lispro to the insulin receptor
and its immunogenicity [3, 9] are, however, not affected
by the mutations.
X-ray crystallography [10, 11] shows that dimer
formation occurs mainly by nonpolar interactions in-
volving B23-B26 and B28 in the C-terminal region of the
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B24 and B26 [11]. In the A-chain, AsnA21 seems to be the
only amino acid that is involved in dimer formation.
More evidence of the importance of the B chain inter-
face in wild-type insulin (shown in Scheme 2) comes
from the observation that insulin mutants without
B26-B30 and B28-B30 regions do not dimerize [12].
Formation of hexamers occurs by burial of both polar
and nonpolar residues between the dimers leading to
looser packing than that of the dimer [2, 11, 13]. Six
GluB13 are arranged in a circular pattern at the center of
the hexamer, with charge repulsion counteracted by
Zn-binding [3]. When GluB13 is changed to Gln, a
slow-acting insulin results [13] owing to a reduction of
charge repulsion and an increase in hexamerization.
Our hypothesis is that mass spectrometry combined
with H/D amide exchange and mathematical modeling
can reveal the effects of mutations on the oligomeriza-
tion properties of proteins, and specifically on various
insulins. We report here a mass spectrometric method
to determine the self-association properties of proteins,
and we apply the method to insulin. We also wish to
Scheme 1. The sequence of human insulin. Insulin consists of
two chains, A and B, having 21 and 30 amino acids, respectively.
The amino acids that are changed to obtain various insulin
mutants (the mutations are shown in Tables 1 and 2) are labeled
with the chain name, followed by the amino acid number in the
chain.
Scheme 2. The dimer interface for the human insulin. A stron-
ger, more compact dimer results because orientation of ProB28 is
towards the interface forming a hydrophobic contact. Coordinates
were taken from RCSB Protein Data Bank, file 1ZNI.pdb.resolve issues with solubility of insulin in the earlier
kinetic results reported in [14], a report in which the
kinetics of amide exchange was used without modeling
to distinguish various forms of insulin. We now fit the
data for r-human, lispro, porcine, and bovine insulins,
whose sequences are shown in Table 1, to a kinetic
model similar to the one used in [15]. Exchange reac-
tions for proteins and peptides were successfully mod-
eled as pseudo first-order reactions [16], and three
exchange rate grouping models were previously ap-
plied to the kinetics of exchange of other proteins [15].
H/D amide exchange is useful for studying the
higher order structure of proteins in solution [17, 18]. Its
use in mapping protein/protein interfaces was pio-
neered by Komives and coworkers [19, 20]. The premise
for their strategy is that amides buried in an interface
will exchange more slowly in the complex than when
the protein is free and not part of a complex. H/D
exchange can also provide thermodynamic information
about protein/ligand binding [21]. Two H/D exchange
methods, SUPREX [21] and PLIMSTEX [22], make use
of H/D exchange in a titration format to obtain the
free-energy and affinity for the binding. To adapt
PLIMSTEX to self-association requires the mathematical
modeling of PLIMSTEX to be changed (no modifica-
tions are required for SUPREX). In this paper, we
describe those modifications and apply the modified
method, which we call SIMSTEX (self interactions by
mass spectrometry self-titration and H/D exchange) to
Scheme 3. The dimer interface for the lispro dimer. An impor-
tant hydrophobic contact in the dimer is eliminated because the
ProB29 is away from the interface. Coordinates were taken from
RCSB Protein Data Bank, file 1LPH.pdb.
Table 1. Sequence variations for insulin analogs studied here
compared to human insulin
Insulin type Sequence variation
Lispro KB28 and PB29 reversed
Bovine A in B30
Porcine A in B30, A in A8 and V in A10
1528 CHITTA ET AL. J Am Soc Mass Spectrom 2006, 17, 1526–1534r-human insulin and to various insulin analogs to
obtain affinity constants for self-association. The vari-
ous insulins were designed by others to increase or
decrease hexamerization [2, 3] as can be seen by con-
sidering the interface between two insulin molecules in
the dimer in Scheme 2.
Methods
Materials
r-Human Insulin was purchased from Sigma (Milwau-
kee, WI). Porcine, bovine, and lispro insulins were gifts
from the Food and Drug Administration of St. Louis.
Other insulin mutants were donated by Dr. Stephen
Bayne of NovoNordisk, Denmark, and were formed by
mutating one or two residues at a time of human insulin
[the list of mutants, their names (as used in this article),
and the corresponding mutation(s) are shown in Table
2]. All the insulin analogs were dissolved in 10-mM
ammonium acetate at pH 2.5. The pHwas then raised to
7.4 by slowly adding ammonia. The solution was then
centrifuged, and the supernatant supersaturated solu-
tion was taken for study.
To obtain an independent assessment of the oli-
gomerization state of insulin in solution, hydrodynamic
diameter distributions for the protein solutions were
determined by dynamic light scattering (DLS) under
both pH conditions. A Brookhaven Instruments Co.
(Holtsville, NY) DLS system consisting of a model
BI-200SM goniometer, a model EMI-9865 photomulti-
plier, and a model 95-2 Ar ion laser (Lexel Corp., Palo
Alto, CA) operated at 514.5 nm was employed. All
measurements were made at 20  1 °C. Before analysis,
insulin solutions were centrifuged for 4 min at 8000  g
in a Brinkman model 5415 microfuge to sediment any
extraneous particles. Scattered light was collected at a
scattering angle 90°. The system’s digital correlator was
operated with 522 channels, ratio channel spacing,
initial and final delay settings between 1.4 s and 10 ms,
respectively, and duration of 10 min. A photomultiplier
aperture of 200 or 400 m was used, and the incident
laser intensity was adjusted to obtain a photon counting
rate of 200 to 300 kcps. Only measurements for which
the measured and calculated intensity autocorrelation
function agreed to within 0.1% were used to calculate
hydrodynamic diameters. Calculations of the hydrody-
namic diameter distribution from measured intensity
Table 2. Insulin mutants studied in this work
Insulin mutant Mutation
A4A17 GluA4 and GluA17 to Gln and TyrB31
B27 ThrB27 to Arg
A4B27 GluA4 to Gln and ThrB27 to Arg
B9Asp SerB9 to Asp
B21 GluB21 to Gln
B13B21 GluB13 and GluB21 to Glnautocorrelation functions were performed with theISDA software package (Brookhaven Instruments Co.,
Holtsville, NY), which employed single exponential
fitting, cumulant analysis, and non-negatively con-
strained least-squares (NNLS), and continuous regular-
ization (CONTIN) analysis routines. Reported hydro-
dynamic diameter distribution averages are mean
values of a minimum of three determinations.
For amide H/D exchange studies, the insulin in
ammonium acetate was diluted 10-fold in deuterated
ammonium acetate. For kinetics measurements, the
uptake of deuterium was monitored as a function of the
time for quenching the reaction in ice-cold water/
acetonitrile/formic acid 50/49/1. To follow the deute-
rium uptake as a function of concentration, the H/D
exchange was allowed to reach steady-state (6 h). The
exchange was quenched, and the solution at a final
insulin concentration of 10 Mwas infused into the ESI
source for MS measurement. The quench caused the
oligomers to dissociate into monomers. The deuterium
uptake was measured as the difference between the
mass centroids of the monomer distribution after and
before exchange.
Mass Spectrometry
Mass spectra of the dimer in various solvents were
acquired with a Q-TOf-Ultima (Micromass, Manchester,
UK), a tandem mass spectrometer consisting of a quad-
rupole (Q) mass analyzer, a quadrupole collision cell,
and a second-stage time-of-flight (TOF) analyzer. Posi-
tive ions were formed by using a needle voltage of 3 kV
and a cone voltage of 90 V. The temperatures of the
source block and for desolvation were 90 °C. A solution
flow rate of 10 L/min was used for introduction. All
parameters (i.e., aperture to the TOF, transport voltage)
were optimized to achieve maximum sensitivity and a
mass resolving power of 10,000 (full width at half
maximum). The spectra were a sum of 2-sec scans over
2 min, and the spectra were smoothed twice using a
three-point Savitzky-Golay method before submitting
the data to the Mathcad (MathSoft Engineering &
Education Inc., Cambridge, MA) program for calculat-
ing the centroids.
Modeling
For kinetic modeling, the total number of active hydro-
gens (sites) was divided into three groups. The number
of exchanging hydrogens in each group and the rate
constant for each group were varied in a process that
minimized the differences between the data and the
model at various time-points. The deuterium uptake is
the sum of number of exchangeable sites in each of the
three groups. Deuterium uptake at each site was mod-
eled as a pseudo first-order reaction to calculate the
fraction of molecules that were deuterated at this site
[15]. From this, the mass shift responsible for the shift of
the mass centroid of the isotopic pattern was calculated.The process for calculating the affinity constants
1529J Am Soc Mass Spectrom 2006, 17, 1526 –1534 OLIGOMERIZATION OF INSULINstarts with the model for PLIMSTEX [23]. Specifically,
the modeling of the mass change based on the solution
concentrations was carried over from PLIMSTEX, but
the equations for the oligomer solution concentrations
were modified to accommodate self-association as de-
scribed in [24]. To allow the program to find a reliable
minimum and avoid being trapped in an unreasonable
local minimum, the search was started at “good-guess”
values. Good-guess values were obtained by synthesiz-
ing a model dataset on the basis of the start values, and
then comparing the outcome to the experimental data.
The initial good-guess values were modified until a
good graphical fit was obtained. The “minimize” func-
tion in the program was then used to refine the sought-
after solution by minimizing the square root of the
mean of the squares of the differences between the data
and the model over the concentration range of the
titration. The minimization is a nonlinear, quasi-New-
tonian method i and all the assumptions required for a
NLLS regression are relevant [25].
The program started with guess values for the i
involved in the association of insulin and the known
total protein (ligand) concentration. The model was
based on the reactions shown in eq 1.
2Monomer¡
K12
Dimer
2Dimer¡
K24
Tetramer
DimerTetramer¡
K46
Hexamer
(1)
The unknown parameter i for the system were taken to
be as those defined in eq 2
0 1
1K12
3K24K12
2
5K46K24K12
3
(2)
To give us consistent expressions for the following
equations, 2 and 4 were set to zero. Using i to define
the oligomer concentrations was more economical for
the development of the equation. After solving for the
i, individual affinity constants were obtained as shown
in eq 3
K121
K24
3
1
2
K46
5
31
(3)
Trial values for another model parameter, Di, were also
provided to the program; where Di is the number of
deuteriums protected in the ith oligomer compared with
that in the monomer. For example, D0 is the number ofamide hydrogens protected in the monomer and D1 is
the number protected in the dimer compared to the
monomer, and so on.
The concentration of free ligand in solution was
calculated by numerically integrating (using the “Rk-
adapt”) the function
dLig
dLigT
, which was calculated as a
reciprocal of the
dLigT
dLig
, where [Lig] is the free ligand
concentration in solution and [Lig]T is the total analyt-
ical concentration of the ligand as described in [23].
The mass shift caused by D uptake, D, at any
concentration during the titration was defined as the
number of exchangeable sites in the molecule for each
oligomer weighted by the corresponding fraction of
monomers produced when the oligomer dissociates,
subtracted from the number of exposed sites in the
monomer. Equation 4 is the mathematical form of this
description. Here N is 5.
D f(Lig,,D)D0
j1
N
Dj
(j 1)jLig
j

i0
N
(i 1)iLig
i
(4)
Each term in eq 4 contained a solution fraction arising
from the oligomer before a common factor of [Lig] had
been used to divide both the denominator and the
numerator. The denominator is the total number of
protein molecules from all oligomeric forms; that is, the
number of molecules that would be detected in the
mass spectrometer after quenching the amide exchange
reaction. This method assumes that each constituent
molecule has a characteristic number of exchangeable
hydrogens. All the modeling and the plots were done in
Mathcad 2001i (MathSoft, Inc., Cambridge, MA).
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Figure 1. Overlay of hydrodynamic diameter distributions de-
termined by DLS for human insulin at (a) pH 2.5. The mean
diameter of the particles is 3.64 nm, suggesting a mixture of
dimers and monomers in solution. (b) pH 7.4. The mean diameter
of the particles is 5.43 nm, suggesting a mixture of higher
oligomers.
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Oligomers in the Gas Phase
The comparison of the molecular diameters obtained
by DLS (Figure 1) with the values reported [26]
reveals that insulin exists mainly as a mixture of
monomers and dimers at pH 2.5; at pH 7.4, the
mixture contains higher oligomers, mainly hexamers.
To determine if ESI can introduce these oligomers
into the gas-phase, we electrosprayed r-human insu-
lin in ammonium acetate solution (pH  7.4). The
resulting mass spectrum (Figure 2) showed various
oligomers of characteristic charge-state distributions,
similar to the observation made by Robinson and
coworkers [27] for bovine insulin. The resolving
power of the Q-TOF did not permit us to distinguish
the 8 trimer from a 16 hexamer. To obtain evi-
dence for existence of oligomers in solution, we
electrosprayed insulin solutions at different concen-
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Figure 3. Monomer (4) and dimer (7) region
difference in the oligomerization properties in s
and D, respectively.trations to determine whether a variation in the
concentration of oligomers in solution produced a
corresponding change in the oligomeric ions in the
gas-phase. We found appreciable amount of oli-
gomers in the mass spectrum only at the relatively
high concentrations of 100 M and 1 mM (data not
shown) of total protein. The abundance of dimer in
the spectrum is higher for the 1-mM solution, indi-
cating that oligomerization increases with concentra-
tion. The high concentrations may be necessary to
compensate for electrospray-induced dissociation of
the oligomers, which are only held together by a few
noncovalent interactions [2, 10, 11].
Investigating further, we electrosprayed lispro solu-
tions from ammonium acetate at a pH of 7.4 (see Figure
3 for the monomer and dimer regions of the mass
spectrum). We found that the abundance of lispro
dimer in the gas phase was lower than that for r-human,
suggesting that lispro self-associates to a lesser extent in
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with literature reports [9], indicating that ESI mass
spectrometry can screen insulin analogs for self-associ-
ation in solution.
The oligomerization models reported in literature
[28], however, do not consider that a trimer or pentamer
exists in solution. Nevertheless, they are seen in the gas
phase of the mass spectrometer. We suggest that these
gas-phase oligomers result from the dissociation of
solution tetramers and hexamers during the process of
ionization. Thus, the species seen in the gas phase may
not reflect those in solution. To obtain a quantitative
assessment of the oligomerization status of various
insulin mutants in solution, we used H/D amide ex-
change experiments, the results from which are de-
scribed below.
Kinetics of Amide Exchange in Solution
To obtain more information on the self-association and
to differentiate better the oligomerization properties of
various insulins, we followed the kinetics of amide
H/D exchange by quenching the exchange at various
times and monitoring the deuterium uptake by ESI MS.
The H/D exchange was initiated by diluting a stock
solution of insulin to the requisite concentration in a
deuterated buffer. Dilution results in dissociation of
higher oligomers (e.g., hexamers and tetramers), which
are first-order kinetic processes. Insulin follows an EX2
mechanism of exchange as determined in 1968 [29]. On
this basis, we assume that various steps in the reaction
diagram follow an EX2 mechanism of exchange; ex-
change in which the rate-limiting step is the exchange of
the exposed site.
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Figure 4. Time-dependent uptake of deuterium for various in-
sulins in solution. The points are experimental data, and the solid
curves are the best theoretical fit.
Table 3. Number of amide hydrogens in the three kinetic group
Insulin analog No. of fast H’s (kf  3 min
1) No. of int
Porcine 6 ( 1)
Bovine 10 ( 0.5)
r-Human 12 ( 1)
Lispro 9 ( 1) 2The rates of exchange for all the insulins studied here
reach a constant value in 6 h (see Figure 4). Lispro
insulin exchanges 32 deuterium atoms after 6 h, com-
pared with 27 by r-human insulin, and reaches65% of
steady-state value within 3 min after mixing, whereas
r-human insulin reaches only 50% at that time. These
comparisons reveal that lispro insulin is less self-asso-
ciated than r-human insulin. Kinetic studies of H/D
exchange for porcine and bovine insulins give similar
results to those of r-human insulin. Although porcine
insulin is most protected from exchange, the differences
between r-human, bovine, and porcine insulins are
small. These results are similar to the ones obtained
earlier in this laboratory [14] under different solution
conditions.
On the basis of earlier work with insulin [29] and our
own work with calmodulin [15], we assume that kinet-
ics for exchange can be classified in three groups: fast,
intermediate, and slow. Applying the kinetic fit de-
scribed in the Methods section allows us to obtain the
number of hydrogens in each of the three groups (Table
3). Lispro has 21 slow hydrogens compared with 24 for
r-human. Although more amide hydrogens of r-human
insulin exchange more rapidly than those of lispro,
there are more amides that exchange at intermediate
rates for lispro. Some of the slow-exchanging amide
hydrogens of r-human insulin exchange at intermediate
rates for lispro, providing more evidence that lispro
insulin is less self-associated in solution than is r-human
insulin.
Similar to the results in [15], the number of hydro-
gens in the slow group for r-human increases with
binding, indicating that binding protects amide hy-
drogens. This could occur either by burial of active
hydrogens in the oligomer interface(s) or by changes
in stability (H-bonding). Although the kinetics of
exchange differentiate the self-association properties
of various insulins, the difference between lispro and
r-human is surprisingly small, given the large differ-
ence in the solution oligomerization properties.
The kinetic properties of H/D amide exchange of
the various oligomers in solution may not be well
represented by the variation in the mass-centroid
of the single insulin molecule whose mass we mea-
sure. Furthermore, it is not possible to partition the
global kinetic effects among the various oligomers by
doing an experiment at a single concentration. A
titration experiment, similar to the one carried out in
the PLIMSTEX [22] method, should be more informa-
tive.
porcine, bovine, r-Human and lispro insulins
d. H’s (ki  0.2 min
1) No. of slow H’s (ks  0.001 min
1)
9 ( 0.5) 26 ( 0.5)
6 ( 0.5) 25 ( 0.5)
5 ( 0.5) 24 ( 0.5)s for
erme
1
1
1
1 ( 1) 21 ( 0.5)
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Self-Titration, and H/D Exchange (SIMSTEX)
Adapting PLIMSTEX for self-association requires first a
measurement of deuterium uptake for monomeric in-
sulin ions at steady-state exchange (e.g., 6 h as in Figure
4) as a function of the total insulin concentration.
Second, the adaptation requires changes in modeling
the titration curve to give the desired affinity constants.
We call the adaptation of PLIMSTEX for the special case
of self-association, SIMSTEX (see “Modeling” in the
Methods section for a description of the changes).
We measured the deuterium uptake for r-human
insulin at various concentrations after 6 h of exchange.
The deuterium uptake for r-human insulin decreases
gradually with increasing concentration of insulin (see
the points in Figure 5). As the concentration increases,
more oligomerization occurs, resulting in more amide
hydrogens being protected. Fitting the experiment data
with the SIMSTEX model gives, when the best fit is
achieved, the theoretical curve in Figure 5.
As a starting point in applying SIMSTEX, we fol-
lowed [28] the literature and assumed that the oli-
gomerization of r-human insulin occurs by the process:
monomer ^ dimer ^ tetramer ^ hexamer (i.e., D ^
T ^ H). A small value of K24 (see first row of data in
Table 4) means that there is no significant tetrameriza-
tion, leaving the most likely steps in oligomerization to
be D ^ H (i.e., the reaction is monomer ^ dimer ^
hexamer) for r-human insulin. We then fit the data to a
D ^ H model to obtain more accurate values for the
affinity constants, as shown by the data in the row 2 of
Table 4. The Kas calculated for the D ^ H model agree
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Figure 5. Plot of the uptake of deuterium as a function of
solution concentration of r-human insulin. The points are the
experimental data and the curves are the theoretical fit.
Table 4. Results from SIMSTEX modeling on r-human and lispr
tetramerization and hexamerization constants, respectively, and t
Insulin analog Model K12 (M
1) K24 (M
1)
r-Human D ^ T ^ H 5  105 2  103
r-Human D ^ H 7  2  105 –
r-Human (Lit.) 7.5  105
[30]
1.4  105[31]with literature values (from sedimentation equilibrium
and CD) within a factor of 5 [30, 31]. The number of
amides protected upon dimerization and hexameriza-
tion of r-human insulin are 18 and 25, respectively,
compared with 51 exchangeable hydrogens in the
monomer.
Application of SIMSTEX to Various Insulin
Mutants
We studied lispro and the six insulin mutants shown in
Table 2 by measuring the extent of H/D exchange for
each as a function of their solution concentration (see
Figure 6 for four of the mutants). Qualitatively, the
deuterium uptakes and the shapes of the curves are
indicators of the self-associating properties of the pro-
teins. Insulin mutant, A4B27, for example, undergoes
the least exchange at the highest concentration studied
(100 M), suggesting a high extent of self-association
for this mutant in solution. Another mutant, B21, has
the smallest initial slope for the six mutants, suggesting
a low extent of dimerization. To obtain quantitative
information on how these mutations affect the oli-
gomerization properties, we applied SIMSTEX model-
ing.
The best fits to the data (see the curves in Figure 6)
afford a set of oligomerization equilibrium constants
(Table 5). We found that some of the mutations affect
dimerization and hexamerization constants by as much
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Figure 6. Plot of the extent of H/D exchange studied as a
function of concentration for four insulin mutants. The points are
the experimental data, and the solid curves are the theoretical fits
to the data. The blue diamonds represent the data for lispro, the
red squares for the mutant B13B21, the green triangles for the
mutant B9Asp, and the purple asterisks for A4B27.
ulins. K12, K24 and K26/K46 are the dimerization,
i values are number of deuterium protected in the i-th oligomer
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from mutant to mutant.
We now consider the effect of each mutation and the
agreement of the oligomerization equilibrium constants
with literature reports. The exchange of lispro shows
that a small initial decrease in exchange is quickly
replaced by a nearly constant extent of exchange, sug-
gesting either a cessation of the oligomerization or a
formation of oligomers in which no additional amide
hydrogens are protected. We obtained the affinity con-
stants for lispro insulin by using a D^ Tmodel (row 1,
Table 5). This choice of model became obvious when we
found no appreciable hexamerization constant when
using the D ^ T^ H model. The outcome shows that
the equilibrium constant for lispro’s dimerization
agrees within a factor of twenty with that reported in
literature [7]. This discrepancy is probably due to the
small protection afforded upon dimerization (D2 for
lispro  4; data not shown), giving rise to the nearly
horizontal curve for lispro in Figure 6. SIMSTEX, simi-
lar to PLIMSTEX, requires that there be a change in the
extent of H/D exchange upon binding for the method
to work well. Accepting the values as estimates for the
equilibrium constants, we see that lispro has a dimer-
ization constant that is reduced by a factor of 20 times
compared to that of r-human insulin. Moreover, lispro
does not hexamerize in the concentration range studied,
further underscoring its lower tendency to form oli-
gomers. The results are consistent with lispro being a
faster-acting insulin than r-human, which is more per-
sistent in vivo.
The equilibrium constants for dimerization and hexam-
erization of the insulin mutant A4A17 are not strongly
affected by the mutations compared to those for human
insulin (Table 5). We found a small effect on the equilib-
rium constants for the mutants A4 and A17, and this is
consistent with the view that these residues are not
involved in the dimerization or hexamerization. Further-
more, the mutant B27, an analog in which Thr at B27 is
replaced by Arg, does not undergo any significant dimer-
ization but, instead, forms a tetramer and a hexamer to a
much higher extent than does human insulin. This insulin
mutant has the property of prolonged action in vivo
possibly because it has lower solubility (often precipitates
at the site of injection into a human) and absorbs slowly [2,
3, 32]. The mutant A4B27 is more soluble, but its dimer-
Table 5. Oligomerization equilibrium constants for the six insul
residues in r-Human insulin, for which we determined K12  7 
Insulin mutant K12 (M
1)
Lispro 3  2  104
A4A17 2  2  107
B27 –
A4B27 2  1  105
B9Asp 6  3  104
B21 7  3  103
B13B21 5  1  104ization constant is five times less than that of r-humaninsulin. The equilibrium constant to give the hexamer is
reduced by three orders of magnitude but that for forma-
tion of the tetramer is increased. These variations are
possibly due to the change in pI caused by the replace-
ment of Glu with Gln.
The three mutants, B9Asp, B21, and B13B21, have
smaller equilibrium constants for hexamerization than
does r-human insulin. The Asp at B9 (in place of a Ser)
introduces a charge site in the B-chain and decreases
self-association compared with that of r-human insulin
[2, 3, 33, 34]. The replacement of GluB21 to Gln causes
such a significant decrease in self-association that no
appreciable hexamer forms for B21. The mutation is in
a -turn that determines many of the secondary struc-
tural features of the insulin molecule [35]. The equilib-
rium constant for B13-B21 to give a hexamer is greater
than that of B21, underscoring the role of GluB13 in
human insulin in promoting oligomerization. Replace-
ment of Glu with Gln is known to decrease charge
repulsion in the center of the hexamer and, thus,
increase stability [13].
Conclusions
Application of SIMSTEX, a variant of PLIMSTEX, per-
mits the determination of equilibrium constants for
oligomerization of insulin and various insulin mutants.
Changing amino acids B9, B13, B21, and B27 impact
significantly the self-association of insulin. The mutant
B13 forms hexamers more readily than r-human given
the change of Glu to Gln, whereas mutants A4 and A17
undergo little oligomerization of this type, and mutant
B9 (Ser to Asp) shows decreased tendency to self-
associate. These results are in good agreement with
those in the literature, motivating continued develop-
ment and application of SIMSTEX not only for screen-
ing newly designed insulin analogs but also for study-
ing self-association of larger proteins. Nevertheless, the
results reveal a limitation of this approach, and of
PLIMSTEX; that is, there must be for self-association, or
binding, in general, a change in the number of amide
hydrogens protected; evidence for this limitation is seen
in the application of SIMSTEX to lispro.
There is also a serious question about this kinetic
approach to equilibrium. Kinetics come into play in two
steps of the experiment: first in the reorganization of the
utants. The mutants were obtained by changing various
(M1) and K26  2  10
9 (M2)
K24 (M
1) K26 or K46
3  2  102 –
– 5.1  0.3  1010 (M2)
1  1  1014 3  3  1011 (M1)
2.0  0.3  105 2  1  106 (M1)
8  1  105 3  1  104 (M1)
2  2  106 –
1  1  107 3  2  105 (M1)in m
105protein when its solution is diluted by adding D2O to
1534 CHITTA ET AL. J Am Soc Mass Spectrom 2006, 17, 1526–1534start the exchange, and second in the actual kinetics of
H/D exchange. How do the kinetics of these steps affect
the SIMSTEX curves (and by analogy PLIMSTEX
curves)? We currently assume in their application that
the reorganization of the oligomer steady-state occurs
rapidly when its solution is diluted with D2O at the
start of the exchange and that the H/D exchange
follows an EX2 mechanism. Preliminary simulations in
our laboratory show that the dissociation/association
kinetics can distort the shape of the curve (i.e., the
response that we observe as a mass shift versus insulin
concentration). We find that the distortion is reduced to
a level of no practical consequence for the determina-
tion of the oligomerization equilibrium constants if the
H/D exchange kinetics are sufficiently slow compared
with the dissociation/association kinetics. For insulin
after 6 h of exchange, those exchange reactions involv-
ing amide hydrogens that exchange at fast and inter-
mediate rates (Table 3) are essentially complete. This
would leave only the amide hydrogens counted as slow
in Table 3 to contribute to the changes in deuterium
uptake as a function of insulin solution concentration
shown in Figures 5 and 6. Simulation also suggests that
the hydrogen–deuterium exchange rate constants of
0.001 min1 and less are sufficiently small to produce
minimal distortion in the SIMSTEX curves. The reason-
able agreement of the equilibrium constants with those
reported supports this conclusion, but future work is
planned to examine these questions in more detail.
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